TABLE 3.
ALV sensitivities of serially passaged and engineered ALV-resistant viruses
| Virus | EC50 | Fold resistanceb |
|---|---|---|
| Wild-type EAV control | ||
| EAVwt | 4.5 ± 0.2 | 1.0 |
| rEAVwt | 2.3 ± 0.3 | 1.0 |
| EAV ALV-1 | ||
| Passage 10 virus | 33.8 ± 5.8 | 7.4 |
| rEAV nsp2H114R | 4.6 ± 0.1 | 2.0 |
| rEAV nsp5A134V | 4.3 ± 0.1 | 1.9 |
| rEAV nsp2H114R + nsp5A134V | 8.9 ± 0.3 | 3.9 |
| rEAV nsp2H114R + nsp5A134V + GP4Y151C | 9.7 ± 0.5 | 4.2 |
| EAV ALV-2 | ||
| Passage 10 virus | ∼12.7a | 2.8 |
| rEAV nsp2H114R | 4.6 ± 0.1 | 2.0 |
| rEAV nsp5Q21R+M62T | 3.5 ± 0.2 | 1.9 |
| rEAV nsp2H114R + nsp5Q21R+M62T | 14.3 ± 1.0 | 6.2 |
| rEAV nsp2H114R + nsp5Q21R+M62T + GP2H11L | 13.2 ± 5.5 | 5.8 |
| rEAVQYA + nsp2H114R | ∼20.0a | 8.7 |
a
The EC50 is an estimated value (labeled “ambiguous” during GraphPad data analysis), due to the fact that the EC50 approached the CC50 for ALV in Huh7 cells, leaving only a few data points between the two values.
b
Fold resistance of both P10 viruses relative to EAVwt; for the engineered rEAV ALV mutants fold resistance was calculated relative to the rEAVwt value.